Lifeclean Q2’23: First take – flat sales development - Redeye

Redeye saw sales and results that were below our expectations. Sales were more or less flat y/y while costs were higher than expected. PFAS represented 37% of sales in the quarter, while the patented Lifeclean products grew by 92% in the quarter. We expect to make minor negative estimates and fair value range changes.

Länk till analysen i sin helhet: https://www.redeye.se/research/940084/lifeclean-q223-first-take-flat-sales-development?utm_source=finwire&utm_medium=RSS